951 resultados para Receptor, Serotonin, 5-HT1A
Resumo:
Pós-graduação em Medicina Veterinária - FMVZ
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Pós-graduação em Medicina Veterinária - FMVZ
Resumo:
Pós-graduação em Patologia - FMB
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Although angiotensin II-induced venoconstriction has been demonstrated in the rat vena cava and femoral vein, the angiotensin II receptor subtypes (AT1 or AT2) that mediate this phenomenon have not been precisely characterized. Therefore, the present study aimed to characterize the pharmacological receptors involved in the angiotensin II-induced constriction of rat venae cavae and femoral veins, as well as the opposing effects exerted by locally produced prostanoids and NO upon induction of these vasomotorresponses. The obtained results suggest that both AT1 and AT2 angiotensin II receptors are expressed in both veins. Angiotensin II concentration–response curves were shifted toward the right by losartan but not by PD 123319 in both the vena cava and femoral vein. Moreover, it was observed that both 10−5 Mindomethacin and 10−4 M L-NAME improve the angiotensin II responses in the vena cava and femoral vein. In conclusion, in the rat vena cava and femoral vein, angiotensin II stimulates AT1 but not AT2 to induce venoconstriction, which is blunted by vasodilator prostanoids and NO.
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Tricyclic antidepressants, such as amitriptyline, are inhibitors of serotonin and norepinephrine neuronal reuptake and this action has been implied in changes in pain threshold supporting its use to alleviate neuropathic pain. Although is known that 1 adrenoceptors participate in the antinociceptive effect of amitriptyline it is unclear which receptor subtype is the target for the increased synaptic levels of norepinephrine resultant from the inhibition of neuronal uptake. Paradoxically, several tricyclic antidepressants including amitriptyline also behave as antagonists of 1 adrenoceptors with different affinities for its subtypes: these drugs have 10 to 100-fold higher affinities for 1A than for 1B and 1D adrenoceptors. This work investigated the involvement of 1 adrenoceptors subtypes in the antinociceptive effect of the amitriptyline in a constriction of the sciatic nerve in rats by determining the effects of subtype selective 1 adrenoceptors antagonists. Fifteen days later, mechanical hyperalgesia was analyzed in a Randall-Selitto test. The 1A-selective antagonist RS100329 was the most potent antagonist of the contractions of the rat prostate, whereas the 1D-selective antagonist BMY 7378 (up to 100g/Kg) was unable to affect these contractions. The antagonist prazosin, BMY 7378 and 5-methyl urapidil inhibited the antinociceptive effect of the amitriptyline. However, the highly selective 1A adrenoceptor antagonist RS100329 was unable to affect the antinociception induced by amitriptyline. These results point out that 1B and/or 1D adrenoceptors, but not 1A, are involved in the antinociceptive effects of amitriptyline
Resumo:
A leptina é um hormônio protéico produzido por adipócitos que atua no sistema nervoso central (SNC) modulando as respostas metabólicas e cardiorrespiratórias. Estudos prévios demonstraram que a leptina ativa receptores do sistema melanocortina (MC3/4R) para modular a ingestão de alimentos e a atividade simpática, no entanto a função dos MC3/4R no controle ventilatório ainda não foi completamente elucidada. Dessa forma, o objetivo do estudo foi de avaliar a função do sistema melanocortina e da leptina sobre as respostas cardiovasculares, metabólicas e ventilatórias. Foram utilizados ratos Holtzman (n=6/grupo) implantados com cânula guia no ventrículo lateral (VL) para a administração de leptina (5 μg/3 μl/dia), de SHU9119, antagonista MC3/4R (0,6 nmol/3 μl/dia) ou do tratamento combinado (SHU+LEP) durante sete dias consecutivos. Após o sexta dia de tratamento, foram analisadas a resposta ventilatória (VE) durante a ativação do quimiorreflexo por hipercapnia (7% CO2) pelo método de pletismografia e o índice metalóbico pela análise do consumo de O2 e da produção de CO2 pelo método de calorimetria indireta. A pressão arterial media (PAM) e a frequência cardíaca (FC) foram avaliadas no sétimo dia de tratamento por meio de catéter intravenoso. A leptina injetada no VL reduziu a ingestão alimentar (~70%) e o peso corporal (~17%), promoveu um aumento no volume corrente (12±0.4 ml.kg-1, ...
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)